

Supplementary Table 3. Univariable and multivariable analyses of baseline clinicopathologic factors for invasive disease-free survival

Variable	Univariable analysis		Multivariable analysis	
	HR (95% CI)	<i>p</i> value	HR (95% CI)	<i>p</i> value
T				
T1a	1			
T1b	0.64 (0.26–1.54)	0.32		
Operation				
BCS	1			
Mastectomy	1.12 (0.46–2.70)	0.809		
Lymphatic invasion				
None	1			
Present	0.39 (0.05–3.07)	0.374		
Hormone receptor				
Negative	1			
Positive	1.48 (0.62–3.50)	0.378		
Ki67				
≤ 20	1			
> 20	0.83 (0.34–2.01)	0.671		
Ki67				
≤ 14	1			
> 14	0.74 (0.27–2.05)	0.565		
p53				
Negative	1		1	
Positive	2.33 (0.90–6.02)	0.08	2.28 (0.87–5.97)	0.092
RT				
No	1			
Yes	0.85 (0.35–2.05)	0.712		
Chemotherapy				
No	1			
Yes	0.65 (0.27–1.53)	0.321		
Anti-HER2				
No	1		1	
Yes	0.49 (0.14–1.67)	0.255	0.47 (0.13–1.73)	0.256
ET				
No	1			
Yes	0.94 (0.38–2.00)	0.613		
Treatment				
None			1	
Chemotherapy only	0.79 (0.31–2.00)	0.613	0.93 (0.36–2.39)	0.869
Chemotherapy + antiHER2	0.44 (0.12–1.61)	0.214	NA	NA

HR, hazard ratio; CI, confidence interval; BCS, breast-conserving surgery; Ki-67, Ki-67 labeling index; p53, tumor protein p53; RT, radiotherapy; HER2, human epidermal growth factor receptor 2; ET, endocrine therapy; NA, not available.